The discontinuation of the Mastersizer 2000 and the gradual transition away from the Zetasizer Nano series are prompting many pharmaceutical laboratories to review how they maintain validated particle characterization methods. For many laboratories, upgrading to a supported platform is now unavoidable, but ensuring data continuity and GMP compliance requires more than simply replacing the instrument.
Installing a new analyzer is relatively straightforward. Demonstrating that historical batch data, established product specifications, and validated parameters remain comparable is the real challenge.
Why Method Transfer Matters
In a GMP environment, the analytical instrument is inextricably linked to the method. When an instrument like the Mastersizer 2000 reaches the end of its supported lifecycle, meaning no spare parts, no servicing, and increasing software vulnerabilities, it introduces an unacceptable regulatory and business risk.
However, moving to a new platform presents its own challenges. Without a robust method transfer, laboratories face:
Data Discontinuity: Historical comparability is lost if the new instrument measures the same sample differently.
Specification Failures: Established quality control specifications may suddenly generate Out of Specification (OOS) results on the new platform.
Costly Redevelopment: Failing to transfer the method correctly can result in months of unnecessary method redevelopment and revalidation.
The goal of a successful transfer is continuity: maintaining validated methods, preserving historical data, and retaining regulatory confidence without starting from scratch.
Why Equivalent Instruments Don’t Always Generate Equivalent Results
A common misconception is that running a validated method on a newer, technically superior instrument will yield identical Particle Size Distribution (PSD) or Dynamic Light Scattering (DLS) results. In reality, two equivalent instruments will frequently produce different data for the exact same sample.
Modern instrument platforms differ not only in hardware but also in how measurement data is acquired, processed, and interpreted.
Optical Design & Detector Geometry: Newer platforms often feature enhanced detector arrays and extended measurement ranges. For instance, the Mastersizer 3000 utilizes a folded optical design and a dual-wavelength system (red laser and blue LED) that captures sub-micron scattering differently than the older Mastersizer 2000 design.
Sample Presentation: Differences in wet dispersion mechanisms, stirring speeds, ultrasound application, and dry powder flow dynamics mean the physical state of the particles during measurement may differ between older and newer models.
Software Algorithms: The way raw light scattering data is translated into a particle size distribution relies on complex mathematical models. Updated software versions and faster processing algorithms may handle these calculations differently, influencing the final results.
Measurement Sensitivity: Upgraded DLS platforms, such as the Zetasizer Ultra, introduce Multi-Angle Dynamic Light Scattering (MADLS), capturing data differently than the Non-Invasive Back Scatter (NIBS) technology used in the older Nano ZS.
Because of these variables, an expert-led transfer process is necessary to align analytical outputs, rather than simply copying parameters from one instrument to another.
Best Practices for a Successful Method Transfer
A robust method transfer should follow the lifecycle management principles outlined in ICH Q14, moving beyond simple parameter input to a scientifically justified bridging process.
Risk Assessment: Identifying which product specifications are most sensitive to instrument changes before the transfer begins.
Method Review & Parameter Optimization: Carefully translating settings such as obscuration limits, stirring speeds, and measurement durations to match the physical characteristics of the new system and its dispersion units.
Verification: Conducting side-by-side testing using identical samples to evaluate the precision, repeatability, and robustness of the transferred method.
Statistical Comparison: Utilizing appropriate statistical approaches to demonstrate equivalence between historical data generated on the legacy instrument and data produced by the new platform.
Documentation: Providing the rigorous GMP documentation required to support regulatory inspections and audits.
Two Real-World Scenarios in Particle Characterization
Although these principles apply broadly across particle characterization techniques, two transitions are currently of particular relevance to pharmaceutical laboratories.
-
The Immediate Need: Mastersizer 2000 to Mastersizer 3000
From 2025 onwards, laser diffraction analyses performed on the Malvern Mastersizer 2000 will no longer be supported under GMP. This represents a critical and immediate risk for pharmaceutical quality control laboratories. Organizations relying on the MS 2000 must transfer their validated wet and dry dispersion methods to the Mastersizer 3000 to maintain operational compliance and avoid disruptions to routine testing.
-
Proactive Future-Proofing: Zetasizer Nano to Ultra
The same considerations apply to laboratories planning the transition from the Zetasizer Nano series to the Zetasizer Ultra. While support for the Nano ZS still exists, the platform is approaching the end of its lifecycle. Planning this transition in advance allows laboratories to preserve long-term data continuity while benefiting from improved analytical capabilities, without the pressure of an urgent migration.
How Kymos Group Supports the Process
Navigating an instrument upgrade without compromising historical data requires specialized expertise. With extensive experience in wet and dry dispersion analysis, as well as DLS and zeta potential measurements, our laboratories have successfully supported the transfer of hundreds of analytical methods for pharmaceutical clients.
We provide comprehensive support throughout the entire process: from initial risk assessment and parameter optimization to method verification and GMP validation documentation aligned with ICH Q14 principles.
Planning the transition before instrument support ends gives laboratories the opportunity to transfer methods in a controlled, scientifically sound manner while maintaining data continuity and GMP compliance.
Contact Kymos Group team to discuss how we can support your next particle characterization method transfer: https://kymos.com/contact/
